Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Public ClinicalTrials.gov record NCT06580002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
Study identification
- NCT ID
- NCT06580002
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of California, Irvine
- Other
- Enrollment
- 75 participants
Conditions and interventions
Conditions
- Breast Cancer
- Sarcoma
- Gastric Cancer
- Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Ovarian Cancer
- Liver Cancer
- Genitourinary Cancer
- Gynecologic Cancer
- Urinary Bladder Cancer
- Leukemia
- Lymphoid Leukemia
- Myeloma Multiple
- Prostate Cancer
- Pancreas Cancer
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- Brain Cancer
- Melanoma
- Mycosis Fungoides
- Kidney Cancer
Interventions
- Riluzole Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2024
- Primary completion
- Jun 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Jul 13, 2026
2024 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chao Family Comprehensive Cancer Center, University of California Irvine | Orange | California | 92868 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06580002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06580002 live on ClinicalTrials.gov.